Latest Triptans Stories
ALISO VIEJO, Calif., April 15, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.
LONDON, Feb. 16, 2015 /PRNewswire/ -- About MigraineMigraine is a complex neurological medicial condition characterized by a severe headache.
DURHAM, N.C., Feb.
Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines. CHICAGO, Jan.
DURHAM, N.C., Jan. 13, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering.
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015-- ALISO VIEJO, Calif., Nov.
Despite the Continued Launch of Generics, the Migraine Market Will Grow by over $2 Billion from 2013 to 2023, According to Findings from Decision Resources BURLINGTON, Mass., Nov.
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S.
ALISO VIEJO, Calif., Oct.
ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.
- Emitting flashes of light; glittering.